Prospective, multicenter, randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of moxifloxacin 400 mg QD for 5 days verus placebo in the treatment of acute bacterial sinusitis.

Trial Profile

Prospective, multicenter, randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of moxifloxacin 400 mg QD for 5 days verus placebo in the treatment of acute bacterial sinusitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2013

At a glance

  • Drugs Moxifloxacin (Primary)
  • Indications Acute sinusitis; Bacterial infections
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 02 Oct 2008 Basic check conducted, last updated 19-09-2008.
    • 21 Sep 2008 Bayer Healthcare Pharmaceuticals added as trial affiliate as reported by ClinicalTrials.gov.
    • 21 Sep 2008 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top